ロルカセリン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ロルカセリン" in Japanese language version.

refsWebsite

Global rank Japanese rank

11nih.gov

4^th place

24^th place

9web.archive.org

1^st place

9doi.org

2^nd place

6^th place

7fda.gov

447^th place

1,043^rd place

3espacenet.com

800^th place

2,213^th place

2drugs.com

399^th place

1,603^rd place

2federalregister.gov

2,474^th place

9,256^th place

2nytimes.com

7^th place

63^rd place

1trademarkia.com

low place

1thehill.com

476^th place

4,439^th place

1semanticscholar.org

11^th place

1,537^th place

1prnewswire.com

406^th place

1,806^th place

1webmd.com

1,169^th place

1,632^nd place

doi.org

“Lorcaserin Hcl for the treatment of obesity”. Expert Opinion on Pharmacotherapy 16 (16): 2531–8. (2015). doi:10.1517/14656566.2015.1096345. PMID 26472579.
“Management of obesity”. Lancet 387 (10031): 1947–56. (May 2016). doi:10.1016/S0140-6736(16)00271-3. PMID 26868660.
“Safety and tolerability of new-generation anti-obesity medications: a narrative review”. Postgraduate Medicine 130 (2): 173–182. (March 2018). doi:10.1080/00325481.2018.1435129. PMC 6261426. PMID 29388462.
“Safety and tolerability review of lorcaserin in clinical trials”. Clinical Obesity 6 (5): 285–95. (October 2016). doi:10.1111/cob.12159. PMID 27627785.
“Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization”. The Journal of Pharmacology and Experimental Therapeutics 325 (2): 577–87. (May 2008). doi:10.1124/jpet.107.133348. PMID 18252809.
Zhu Q, et al. Novel Synthesis of Antiobesity Drug Lorcaserin Hydrochloride. Org. Process Res. Dev. 2015, 19(9): 1263–1267. doi:10.1021/acs.oprd.5b00144
“Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity”. Journal of Medicinal Chemistry 51 (2): 305–13. (January 2008). doi:10.1021/jm0709034. PMID 18095642.
“Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity”. Bioorganic & Medicinal Chemistry Letters 15 (5): 1467–70. (March 2005). doi:10.1016/j.bmcl.2004.12.080. PMID 15713408.
“Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies”. Therapie 60 (5): 441–60. (2005). doi:10.2515/therapie:2005065. PMID 16433010.

drugs.com

“Lorcaserin Use During Pregnancy”. Drugs.com (4 November 2019). 14 January 2020閲覧。
“Lorcaserin New Drug Application”. Drugs.com (22 December 2009). 3 March 2016時点のオリジナルよりアーカイブ。2021年6月14日閲覧。

espacenet.com

worldwide.espacenet.com

US patent 6953787, Brian Smith, Jeffrey Smith, "5HT2c receptor modulators", published 2003-10-04, issued 2005-11-10
US patent 7704993, Brian Smith, Charles A. Gilson, III, Jeffrey Schultz, Jeffrey Smith, "Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases", published 2004-16-06, issued 2010-27-04
US patent 8207158, Brian Smith, Jeffrey Smith, "5HT2c receptor modulators", published 2011-27-05, issued 2012-26-06

fda.gov

“FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”. U.S. Food and Drug Administration (FDA) (14 January 2020). 1 April 2020閲覧。
"FDA approves Belviq to treat some overweight or obese adults". U.S. Food and Drug Administration (FDA) (Press release). 27 June 2012. 2012年9月1日時点のオリジナルよりアーカイブ。2020年1月14日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
“Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug”. U.S. Food and Drug Administration (FDA) (13 February 2020). 18 February 2020閲覧。
“Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)”. U.S. Food and Drug Administration (FDA) (14 January 2020). 14 January 2020閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
“FDA In Brief: FDA Requests Voluntary Withdrawal of Weight-Loss Medication After Clinical Trial Shows an Increased Occurrence of Cancer”. FDA. (2020年2月13日)

accessdata.fda.gov

“Drug Approval Package: Belviq (lorcaserin hydrochloride) Tablets NDA #022529”. U.S. Food and Drug Administration (FDA) (August 7, 2012). 14 January 2020閲覧。
“Belviq XR (lorcaserin hydrochloride) extended-release tablets”. U.S. Food and Drug Administration (FDA) (26 October 2016). 14 January 2020閲覧。

federalregister.gov

“Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV” (2012年12月19日). 2021年6月14日閲覧。
“Department Of Justice Drug Enforcement Administration 21 CFR Part 1308, Placement of Lorcaserin into Schedule IV” (2013年5月8日). 2021年6月14日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

“Lorcaserin Hcl for the treatment of obesity”. Expert Opinion on Pharmacotherapy 16 (16): 2531–8. (2015). doi:10.1517/14656566.2015.1096345. PMID 26472579.
“Management of obesity”. Lancet 387 (10031): 1947–56. (May 2016). doi:10.1016/S0140-6736(16)00271-3. PMID 26868660.
“Safety and tolerability of new-generation anti-obesity medications: a narrative review”. Postgraduate Medicine 130 (2): 173–182. (March 2018). doi:10.1080/00325481.2018.1435129. PMC 6261426. PMID 29388462.
“Safety and tolerability review of lorcaserin in clinical trials”. Clinical Obesity 6 (5): 285–95. (October 2016). doi:10.1111/cob.12159. PMID 27627785.
“Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization”. The Journal of Pharmacology and Experimental Therapeutics 325 (2): 577–87. (May 2008). doi:10.1124/jpet.107.133348. PMID 18252809.
“Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity”. Journal of Medicinal Chemistry 51 (2): 305–13. (January 2008). doi:10.1021/jm0709034. PMID 18095642.
“Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity”. Bioorganic & Medicinal Chemistry Letters 15 (5): 1467–70. (March 2005). doi:10.1016/j.bmcl.2004.12.080. PMID 15713408.
“Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies”. Therapie 60 (5): 441–60. (2005). doi:10.2515/therapie:2005065. PMID 16433010.